UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
Cambridge, MA | ||
(Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code): (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01 | Entry into a Material Definitive Agreement. |
On April 5, 2021, Mersana Therapeutics, Inc. (the “Company”), entered into an Eighth Lease Modification Agreement (the “Expansion Agreement”) to the Lease (the “Lease”) with Rivertech Associates II LLC (the “Lessor”), which covers certain laboratory and office space at 840 Memorial Drive, Cambridge, MA 02139 (the “Premises”). The Expansion Agreement, effective as of April 5, 2021, expands the space leased by the Company at the Premises (the “Expansion Space”) for a term of sixty months beginning on July 1, 2021, and ending on June 30, 2026.
The foregoing description of the Amendment is qualified in its entirety by the full text of the Extension Agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2021.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit No. | Description | |
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
MERSANA THERAPEUTICS, INC. |
|
||
|
By: | /s/ Brian DeSchuytner |
|
|
Brian DeSchuytner |
Date: April 9, 2021